{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:36:27Z","timestamp":1790847387214,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1838-6","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T10:05:23Z","timestamp":1549965923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-0308","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Vercruysse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lifermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Balageas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delbrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"7","key":"1838_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/ard.54.7.587","volume":"54","author":"G Magadur-Joly","year":"1995","unstructured":"Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still\u2019s disease: estimate of the incidence by a retrospective study in West France. Ann Rheum Dis. 1995;54(7):587\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1838_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","volume":"30","author":"S Casta\u00f1eda","year":"2016","unstructured":"Casta\u00f1eda S, Blanco R, Gonz\u00e1lez-Gay MA. Adult-onset Still\u2019s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30(2):222\u201338.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1\u20132","key":"1838_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","volume":"61","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, S\u00e8ve P. Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1\u20132):53\u201362.","journal-title":"Immunol Res"},{"issue":"11","key":"1838_CR4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","volume":"13","author":"ATJ Maria","year":"2014","unstructured":"Maria ATJ, Le Quellec A, Jorgensen C, Touitou I, Rivi\u00e8re S, Guilpain P. Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149\u201359.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1838_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, S\u00e8ve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13(7):708\u201322.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"1838_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","volume":"40","author":"T Fujii","year":"2001","unstructured":"Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still\u2019s disease. Association with chronic articular disease. Rheumatology. 2001;40(12):1398\u2013404.","journal-title":"Rheumatology"},{"issue":"2","key":"1838_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","volume":"61","author":"M Shimizu","year":"2013","unstructured":"Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345\u20138.","journal-title":"Cytokine"},{"issue":"9","key":"1838_CR8","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010;49(9):1645\u201353.","journal-title":"Rheumatology"},{"issue":"4","key":"1838_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/acr.22194","volume":"66","author":"H Ichida","year":"2014","unstructured":"Ichida H, Kawaguchi Y, Sugiura T, Takagi K, Katsumata Y, Gono T, et al. Clinical manifestations of adult-onset Still\u2019s disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res. 2014;66(4):642\u20136.","journal-title":"Arthritis Care Res"},{"key":"1838_CR10","doi-asserted-by":"crossref","unstructured":"Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still\u2019s disease: from pathophysiology to targeted therapies. Int J Inflamm [Internet]. 2012;2012. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3390042\/","DOI":"10.1155\/2012\/879020"},{"issue":"1","key":"1838_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.clim.2004.03.023","volume":"112","author":"O Saiki","year":"2004","unstructured":"Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still\u2019s disease reflects a Th2 rather than a Th1 cytokine profile. Clin Immunol Orlando Fla. 2004;112(1):120\u20135.","journal-title":"Clin Immunol Orlando Fla"},{"key":"1838_CR12","doi-asserted-by":"crossref","unstructured":"Efthimiou P, Moorthy LN, Mavragani CP, Skokos D, Fautrel B. Adult onset Still\u2019s disease and autoinflammation. Int J Inflamm [Internet]. 2012;2012. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3437651 \/.","DOI":"10.1155\/2012\/964751"},{"key":"1838_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167\u201371.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1838_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","volume":"32","author":"H Boysson de","year":"2013","unstructured":"de Boysson H, F\u00e9vrier J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still\u2019s disease: current clinical evidence. Clin Rheumatol. 2013;32(1):141\u20137.","journal-title":"Clin Rheumatol"},{"issue":"16","key":"1838_CR15","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2169\/internalmedicine.50.4771","volume":"50","author":"Y Yoshida","year":"2011","unstructured":"Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab improved both clinical and laboratory manifestations except for Interleukin-18 in a case of multiple drug-resistant adult-onset Still\u2019s disease. Intern Med. 2011;50(16):1757\u201360.","journal-title":"Intern Med"},{"issue":"Suppl 1","key":"1838_CR16","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1007\/s10067-010-1562-8","volume":"32","author":"T Naniwa","year":"2013","unstructured":"Naniwa T, Ito R, Watanabe M, Hayami Y, Maeda S, Sasaki K, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still\u2019s disease. Clin Rheumatol. 2013;32(Suppl 1):S103\u20136.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1838_CR17","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanju\u00e1n","year":"2014","unstructured":"Ortiz-Sanju\u00e1n F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Oliv\u00e9 A, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients: tocilizumab in AOSD refractory to standard treatment. Arthritis Rheumatol. 2014;66(6):1659\u201365.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1838_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.autrev.2017.07.017","volume":"16","author":"M Govoni","year":"2017","unstructured":"Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still\u2019s disease in clinical practice. Autoimmun Rev. 2017;16(10):1016\u201323.","journal-title":"Autoimmun Rev"},{"key":"1838_CR19","doi-asserted-by":"crossref","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still disease. Medicine (Baltimore) [Internet]. 2014 Mar 4 [cited 2015 Dec 18];93(2). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4616309\/","DOI":"10.1097\/MD.0000000000000021"},{"issue":"1","key":"1838_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/ket250","volume":"53","author":"IA Al-Homood","year":"2014","unstructured":"Al-Homood IA. Biologic treatments for adult-onset Still\u2019s disease. Rheumatology. 2014;53(1):32\u20138.","journal-title":"Rheumatology"},{"key":"1838_CR21","doi-asserted-by":"crossref","unstructured":"Ortiz-Sanju\u00e1n F, Blanco R, Riancho-Zarrabeitia L, Casta\u00f1eda S, Oliv\u00e9 A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still\u2019s disease. Medicine (Baltimore) [Internet]. 2015 Oct 2 [cited 2015 Dec 17];94(39). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4616841\/","DOI":"10.1097\/MD.0000000000001554"},{"issue":"5","key":"1838_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro C, Ridene M, Lequerre T, Chalumeau NC, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 2013;65(5):822\u20136.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1838_CR23","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/ar3366","volume":"13","author":"K Laskari","year":"2011","unstructured":"Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study. Arthritis Res Ther. 2011;13(3):R91.","journal-title":"Arthritis Res Ther"},{"key":"1838_CR24","doi-asserted-by":"crossref","unstructured":"Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still\u2019s disease: a multicentre retrospective observational study. Front Pharmacol [Internet]. 2017 Jun 13;8. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00369\/full","DOI":"10.3389\/fphar.2017.00369"},{"issue":"3","key":"1838_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9 T, Quartier P, Rosellini D, Alaoui F, Bandt MD, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1838_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/1744666X.2018.1536548","volume":"14","author":"S Casta\u00f1eda","year":"2018","unstructured":"Casta\u00f1eda S, Atienza-Mateo B, Mart\u00edn-Varillas JL, Serra L\u00f3pez-Matencio JM, Gonz\u00e1lez-Gay MA. Anakinra for the treatment of adult-onset Still\u2019s disease. Expert Rev Clin Immunol. 2018;14(12):979\u201392.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1838_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","volume":"13","author":"P Ruscitti","year":"2017","unstructured":"Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still\u2019s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089\u201397.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1838_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","volume":"44","author":"G Cavalli","year":"2015","unstructured":"Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still\u2019s disease. Scand J Rheumatol. 2015;44(4):309\u201314.","journal-title":"Scand J Rheumatol"},{"key":"1838_CR29","first-page":"933","volume":"26","author":"R Priori","year":"2008","unstructured":"Priori R, Ceccarelli F, Barone F, Iagnocco A, Valesini G. Clinical, biological and sonographic response to IL-1 blockade in adult onset Still\u2019s disease. Clin Exp Rheumatol. 2008;26:933\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1838_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1838_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00296-011-1801-6","volume":"32","author":"H-A Kim","year":"2012","unstructured":"Kim H-A, Sung J-M, Suh C-H. Therapeutic responses and prognosis in adult-onset Still\u2019s disease. Rheumatol Int. 2012;32(5):1291\u20138.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1838_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","volume":"25","author":"S Pay","year":"2006","unstructured":"Pay S, T\u00fcrk\u00e7apar N, Kalyoncu M, Sim\u015fek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still\u2019s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5):639\u201344.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1838_CR33","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum. 2010;62(8):2530\u20135.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1838_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64(2):262\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1838_CR35","first-page":"1","volume":"18","author":"Y Ma","year":"2017","unstructured":"Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis. Mod Rheumatol. 2017;18:1\u201325.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"1838_CR36","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, et al. Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1838_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10(1):19.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1838_CR38","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jbspin.2013.04.011","volume":"80","author":"C Banse","year":"2013","unstructured":"Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerr\u00e9 T, L\u00e9vesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still\u2019s disease. Joint Bone Spine. 2013;80(6):653\u20135.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"1838_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/RHU.0000000000000082","volume":"20","author":"S Barsotti","year":"2014","unstructured":"Barsotti S, Neri R, Iacopetti V, d\u2019Ascanio A, Talarico R, Tripoli A, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. JCR J Clin Rheumatol. 2014;20(2):121.","journal-title":"JCR J Clin Rheumatol"},{"issue":"8","key":"1838_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard.2005.047621","volume":"65","author":"K Ahmadi-Simab","year":"2006","unstructured":"Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Ann Rheum Dis. 2006 Aug 1;65(8):1117\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1838_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","volume":"17","author":"RA Ostrowski","year":"2011","unstructured":"Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset Still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17(6):315\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1838_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4081\/reumatismo.2016.888","volume":"68","author":"N Belfeki","year":"2016","unstructured":"Belfeki N, Smiti Khanfir M, Said F, Hamzaoui A, Ben Salem T, Ben Ghorbel I, et al. Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Reumatismo. 2016 16;68(3):159.","journal-title":"Reumatismo"},{"issue":"2","key":"1838_CR43","first-page":"265","volume":"28","author":"L Quartuccio","year":"2010","unstructured":"Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2010;28(2):265\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1838_CR44","first-page":"657","volume":"31","author":"J Padilla-Ibarra","year":"2013","unstructured":"Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2013;31(4):657\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1838_CR45","first-page":"888","volume":"27","author":"E Bartoloni","year":"2009","unstructured":"Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still\u2019s disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol. 2009;27(5):888\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1838_CR46","doi-asserted-by":"crossref","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, K\u00f6tter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis. 2018;annrheumdis \u2013 2017\u2013212608.","DOI":"10.1136\/annrheumdis-2017-212608"},{"issue":"12","key":"1838_CR47","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/rheumatology\/keq284","volume":"49","author":"D-Y Chen","year":"2010","unstructured":"Chen D-Y, Chen Y-M, Lan J-L, Lin C-C, Chen H-H, Hsieh C-W. Potential role of Th17 cells in the pathogenesis of adult-onset Still\u2019s disease. Rheumatol Oxf Engl. 2010;49(12):2305\u201312.","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"1838_CR48","first-page":"2422","volume":"30","author":"J-H Choi","year":"2003","unstructured":"Choi J-H, Suh C-H, Lee Y-M, Suh Y-J, Lee S-K, Kim S-S, et al. Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol. 2003 Nov;30(11):2422\u20137.","journal-title":"J Rheumatol"},{"key":"1838_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1460230","volume":"13","author":"T Mimura","year":"2018","unstructured":"Mimura T, Kondo Y, Ohta A, Iwamoto M, Ota A, Okamoto N, et al. Evidence-based clinical practice guideline for adult Still\u2019s disease. Mod Rheumatol. 2018;13:1\u201353.","journal-title":"Mod Rheumatol"},{"key":"1838_CR50","doi-asserted-by":"crossref","unstructured":"Guilpain P, Le Quellec A, Maria ATJ. Therapeutic innovation in adult-onset Still\u2019s disease (and other rare inflammatory disorders): how to secure evidence-based medicine? Ann Rheum Dis. 2018;77:1699\u2013701.","DOI":"10.1136\/annrheumdis-2018-213106"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1838-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T15:48:36Z","timestamp":1662911316000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1838-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1838-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors state that they had full access to all the data in the study and they take responsibility for the integrity of the data and the accuracy of the data analysis as well as the decision to submit them for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fran\u00e7ois Vercruysse has no relevant relationship conditions or circumstances that present a potential conflict of interest regarding this study.Thomas Barnetche has no relevant relationships conditions or circumstances that present a potential conflict of interest regarding this study.Estibaliz Lazaro has received consultancy fees from Roche, Novartis, and UCB.Emilie Shipley has no relevant relationships conditions or circumstances that present a potential conflict of interest regarding this study.Fran\u00e7ois Lifermann has no relevant relationships conditions or circumstances that present a potential conflict of interest regarding this study.Alexandre Balageas has no relevant relationships conditions or circumstances that present a potential conflict of interest regarding this study.Xavier Delbrel has no relevant relationships conditions or circumstances that present a potential conflict of interest regarding this study.Bruno Fautrel, Marie-Elise Truchetet, Christophe Richez, and Thierry Schaeverbeke have received consultancy fees and\/or research funding from Abbvie, Bristol-Myers Squibb, Pfizer, Roche, Lilly, Novartis, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"53"}}